Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

• ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock jumped more than 11% in its Friday trading session. The stock’s overall gain during the previous week stood at 6.32%, cutting some of the losses it had incurred in this year so far. Following its recent upswing, the stock’s Year to Date losses are now down to 13%.
The stock saw a revival after the recent announcement of its quarterly results. The company reported its revenue at $1.6 million while its quarterly loss stood at $10.85 million, down from $18.17 million loss it had announced for the corresponding period of the previous year. The company’s per share loss was also down to $0.11, from previous year figure of $0.14.

• Pfizer (PFE) announced the cancellation of it planned euro400 million expansion in Ireland. The company was planning to expand its Grange Castle facility in Dublin. The project would have resulted in permanent employment for 350 people. It also would have created additional 1,250 jobs during the construction phase.
Pfizer is one of the biggest private sector employers in Ireland. The project has apparently been cancelled on account of failure of bococizumab. The drug was designed to control cholesterol by blocking the PCSK9 protein. However, the tests found that the drug tended to gradually lose its potency on controlling LDL cholesterol.

 

• Juno (Juno) announced halting its CAR-T trial following the death of two leukemia patients. This is the second time in less than six month that the trial has been halted.
• Eagleline Acquisition Corp.,a blank-check company concentrating on businesses supplying services to the healthcare industry failed to debut its planned IPO last week. The company is likely to try again to sell 15 million units at $10 per unit to raise $150 million. It will be listed under IGLEU ticker on NASDAQ.

 
• Sinovac Biotech reported its third quarter revenue at $28.7 million, up 71.4% on YoY basis. The company’s net income for shareholders stood at $4.3 million, up from a loss of $1.8 million it suffered in the third quarter of the previous year

• Mark Ledoux, the CEO of Natural Alternative International (NASDAQ:NAII) sold $132.8K worth of shares of the company.

Gainers (% price change) Last Trade Change Mkt Cap
ZIOPHARM Oncology Inc.
ZIOP (NASDAQ)
7.22 +0.77 (11.94%) 999.13M
Cytokinetics, Inc.
CYTK(NASDAQ)
12.45 +0.65 (5.51%) 526.76M
RTI Surgical Inc
RTIX (NASDAQ)
3.05 +0.15 (5.17%) 175.18M
Impax Laboratories Inc
IPXL (NASDAQ)
15.10 +0.65 (4.50%) 1.17B
Insmed Incorporated
INSM(NASDAQ)
15.22 +0.65 (4.46%) 965.64M
Losers (% price change)
Concord Medical Services
CCM (NYSE)
4.20 -0.23 (-5.19%) 185.44M
Amicus Therapeutics, Inc.
FOLD (NASDAQ)
8.90 -0.33 (-3.58%) 1.30B
Endologix, Inc.
ELGX (NASDAQ)
7.59 -0.26 (-3.31%) 654.30M
AcelRx Pharmaceuticals
ACRX (NASDAQ)
3.05 -0.10 (-3.17%) 138.27M
MediciNova, Inc.
MNOV(NASDAQ)
7.13 -0.23 (-3.13%) 244.24M
Most Actives (dollar volume)
Eli Lilly and Co
LLY (NYSE)
69.12 +1.12 (1.65%) 68.28B
Johnson & Johnson
JNJ (NYSE)
114.13 +1.06 (0.94%) 311.40B
Bristol-Myers Squibb Co
BMY (NYSE)
56.98 +0.23 (0.41%) 95.56B
Pfizer Inc.
PFE (NYSE)
31.69 +0.27 (0.86%) 192.86B
Amgen, Inc.
AMGN (NASDAQ)
145.34 +0.31 (0.21%) 108.65B